Detailed demographic characteristics of treated diabetes participants (n=17)
| Variable | Total participants |
| Pre-existing comorbidities | |
| Hypertension | 15 (88%) |
| Dyslipidemia | 16 (94%) |
| Ischemic heart disease | 4 (23 %) |
| Atrial fibrillation | 0 (0 %) |
| Stroke | 2 (11.8 %) |
| Transient ischemic attack | 1 (6%) |
| Peripheral vascular disease | 1 (6 %) |
| Diabetic microvascular complications | |
| Diabetic retinopathy | 5 (29 %) |
| Diabetic kidney disease | 7 (41 %) |
| Types of dyslipidemia medication | |
| Statin | 14 (82 %) |
| Fibrate | 1 (6 %) |
| Ezetimibe | 1 (6 %) |
| Antihypertensive medication use during trial | |
| Beta blocker | 2 (11.8%) |
| Calcium channel blocker | 5 (29 %) |
| Thiazide diuretic | 1 (6 %) |
| Types of diabetes medication | |
| Metformin | 16 (94%) |
| Sulfonylurea | 4 (23 %) |
| Dipeptidyl peptidase 4 inhibitor | 1 (6 %) |
| Glucagon-like peptide 1 receptor agonist | 2 (11.8 %) |
| Thiazoledinedione | 0 (0%) |
| Acarbose | 1 (6 %) |
| Insulin basal | 2 (11.8 %) |
| Insulin bolus | 2 (11.8 %) |
| Insulin premix | 2 (11.8 %) |
| Smoking status | |
| Currently not smoking | 10 (58 %) |
| Currently smoking | 3 (17.6%) |
| Previous smoking | 5 (29 %) |
Data are expressed as number (percentage).